Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernews.google.com
durvalumab multiple myeloma - Google News
Get the latest updates from durvalumab multiple myeloma - Google News directly as they happen.
Follow now < 10 followers
Latest posts
Last updated 8 months ago
Head and Neck Cancer Market Future Scope and Latest Trends Analysis Report - Benzinga
8 months ago
Head and Neck Cancer Market Future Scope and Latest Trends Analysis Report...
Durvalumab by AstraZeneca for Chronic Lymphocytic Leukemia ... - Pharmaceutical Technology
8 months ago
Durvalumab by AstraZeneca for Chronic Lymphocytic Leukemia ... Pharmaceutical Technology
An Abundance of Approaches Moves Discussion of Sequencing to ... - Targeted Oncology
8 months ago
An Abundance of Approaches Moves Discussion of Sequencing to ... Targeted Oncology
Active Biotech Interim Report Q2 2023 - Marketscreener.com
8 months ago
Active Biotech Interim Report Q2 2023 Marketscreener.com
Multiple Myeloma Market and Epidemiolohy 2032: Treatment Market ... - Digital Journal
8 months ago
Multiple Myeloma Market and Epidemiolohy 2032: Treatment Market ... Digital Journal
Sherwood Discusses Treatment Options for Unresectable Stage III ... - Targeted Oncology
8 months ago
Sherwood Discusses Treatment Options for Unresectable Stage III ... Targeted Oncology
Multiple Myeloma Market and Epidemiolohy 2032: Treatment Market, Drugs, Pipeline, FDA Approvals and Compa - Benzinga
8 months ago
Multiple Myeloma Market and Epidemiolohy 2032: Treatment Market, Drugs, Pipeline, FDA Approvals...
Ongoing Trials to Watch in Recurrent Endometrial Cancer - Targeted Oncology
9 months ago
Ongoing Trials to Watch in Recurrent Endometrial Cancer Targeted Oncology
Durvalumab by AstraZeneca for Soft Tissue Sarcoma: Likelihood of ... - Pharmaceutical Technology
9 months ago
Durvalumab by AstraZeneca for Soft Tissue Sarcoma: Likelihood of ... Pharmaceutical Technology
Durvalumab by AstraZeneca for Epithelial Ovarian Cancer ... - Pharmaceutical Technology
9 months ago
Durvalumab by AstraZeneca for Epithelial Ovarian Cancer ... Pharmaceutical Technology
Durvalumab by AstraZeneca for Esophageal Cancer: Likelihood of ... - Pharmaceutical Technology
9 months ago
Durvalumab by AstraZeneca for Esophageal Cancer: Likelihood of ... Pharmaceutical Technology
Durvalumab by AstraZeneca for Mantle Cell Lymphoma: Likelihood ... - Pharmaceutical Technology
9 months ago
Durvalumab by AstraZeneca for Mantle Cell Lymphoma: Likelihood ... Pharmaceutical Technology